[Telithromycin: a new therapeutic option for community-acquired respiratory infection].
Muñoz
M J
MJ
Servicio de Farmacología Clínica, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra.
Azanza
J R
JR
Escolar
M
M
Macaya
A
A
Gil
F J
FJ
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy*; D000075202:Contraindications; D004347:Drug Interactions; D006801:Humans; D048628:Ketolides; D008133:Long QT Syndrome / Q000139:chemically induced; D018942:Macrolides; D015394:Molecular Structure; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin